You are viewing: South Korea Biopharmaceutical Contract Manufacturing Market analysis

The South Korea Biopharmaceutical Contract Manufacturing Market was valued at $317.6 Million in 2025 and projected to reach to $481.5 Million by 2030, representing a compound annual growth rate of 8.7%. South Korea's biopharmaceutical contract manufacturing sector is poised for sustained growth, driven by increasing demand for outsourced manufacturing services from global pharmaceutical companies and rising investments in domestic biotech innovation.

South Korea Biopharmaceutical Contract Manufacturing Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

South Korea Biopharmaceutical Contract Manufacturing Market Trends and Insights

  • South Korea has emerged as a critical hub for contract manufacturing services, driven by its advanced biotechnology infrastructure, skilled workforce, and regulatory expertise.
  • The market in South Korea benefits from strong government support for the life sciences sector and increasing demand from both domestic and international biopharmaceutical companies seeking reliable manufacturing partners. Growth in South Korea's contract manufacturing sector is fueled by rising investments in biologics production, growing outsourcing trends among pharmaceutical companies, and South Korea's strategic position in the Asia Pacific region.
  • South Korea continues to attract multinational pharmaceutical firms seeking cost-effective yet high-quality manufacturing solutions.
  • The expansion trajectory through 2030 reflects South Korea's strengthening competitive position and its capacity to meet escalating global demand for specialized biopharmaceutical manufacturing services..

Key Market Statistics

  • CAGR (2025-2030) 8.7% CAGR
  • Market Size, 2025 ~USD 317.6 Million
  • Forecast, 2030 ~USD 481.5 Million
  • Country South Korea

South Korea Biopharmaceutical Contract Manufacturing Market Overview

Market Valuation & Growth :

South Korea's biopharmaceutical contract manufacturing market is valued at USD 317.6 million in 2025, with a projected CAGR of 8.7% through 2030, reaching USD 481.5 million by forecast end.

Advanced Biotechnology Infrastructure :

South Korea possesses state-of-the-art manufacturing facilities and GMP-compliant infrastructure, positioning it as a preferred destination for global biopharmaceutical companies seeking reliable contract manufacturing partners.

Skilled Workforce & Expertise :

The country boasts a highly educated workforce with specialized expertise in biologics, cell therapy, and vaccine manufacturing, supported by continuous investment in biotechnology talent development and training programs.

Regulatory Competency :

South Korea's regulatory framework aligns with international standards, with MFDS oversight ensuring quality compliance and facilitating faster market entry for contract-manufactured biopharmaceutical products.

South Korea Biopharmaceutical Contract Manufacturing Market Dynamics

  • The country's competitive advantages—including advanced infrastructure, regulatory expertise, and cost-effectiveness compared to Western markets—position it as an attractive alternative manufacturing hub for complex biologics and specialty pharmaceuticals. Looking ahead to 2030, South Korea is expected to strengthen its position in the global CDMO landscape through expansion of manufacturing capacity, development of next-generation therapies (gene therapy, cell therapy), and strategic partnerships with international pharmaceutical firms.
  • Government support for biotechnology clusters and continued R&D investments will further accelerate market expansion and consolidate South Korea's role as a key regional manufacturing center..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Pharmaceuticals

    Top Technologies
    • Bioreactors
    • Analytical Testing
    • Bioanalytical Testing Services
    • Cell Counters
    • Data Management Services
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • SANOFI
    • Pfizer Inc.
    • NOVARTIS

      Key Takeaways

      • South Korea's biopharmaceutical contract manufacturing market is valued at USD 317.6 million in 2025 and will reach USD 481.5 million by 2030.
      • South Korea is experiencing steady growth at 8.7% CAGR, driven by advanced infrastructure and increasing outsourcing demand.
      • South Korea's strategic location and regulatory capabilities position it as a preferred manufacturing destination in Asia Pacific.
      • South Korea's market expansion is supported by government initiatives and rising investments in biologics and specialized manufacturing.

      Biopharmaceutical Contract Manufacturing Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment CELL & GENE THERAPY (Molecule Type)
      Forecast Period 2025-2030
      Growth Rate CAGR of 8.8% from 2025 to 2030
      Largest Segment MAMMALIAN EXPRESSION SYSTEMS (Source)
      Market Size Base Year (Billions) ~USD 22.4 (2025)
      Revenue Forecast (Billions) ~USD 34.15 (2030)
      Segments Covered Service, Type, Scale Of Operation, Source, Molecule Type, Therapeutic Area

      South Korea Biopharmaceutical Contract Manufacturing Market Report Segmentation

      6 segment dimensions are covered across the global market.

      By Service

      • Formulation & Fill-Finish
      • Manufacturing
      • Other Services
      • Packaging & Labeling

      By Type

      • Biologic Drug Product Manufacturing
      • Biologic Drug Substance Manufacturing

      By Scale Of Operation

      • Clinical Operations
      • Commercial Operations

      By Source

      • Mammalian Expression Systems
      • Non-Mammalian Expression Systems

      By Molecule Type

      • Antibody-Drug Conjugates
      • Cell & Gene Therapy
      • Monoclonal Antibodies
      • Other Molecules
      • Therapeutic Peptides & Proteins
      • Vaccines

      By Therapeutic Area

      • Autoimmune Diseases
      • Cardiovascular Diseases
      • Infectious Diseases
      • Metabolic Diseases
      • Neurology
      • Oncology
      • Other Therapeutic Areas

      Target Audience

      • Biopharmaceutical Companies : Global and regional pharma firms seeking reliable contract manufacturing partners in South Korea need detailed market insights to evaluate CDMO capabilities, capacity, and regulatory compliance for outsourcing decisions.
      • Contract Manufacturing Organizations (CDMOs) : Existing and prospective CDMOs operating in South Korea require market data to benchmark performance, identify growth opportunities, assess competitive positioning, and plan capacity expansion strategies.
      • Investment & Private Equity Firms : Investors evaluating opportunities in South Korea's biotech sector need comprehensive market analysis to assess growth potential, identify acquisition targets, and make informed capital allocation decisions.
      • Regulatory & Compliance Consultants : Consultants advising clients on South Korea market entry require detailed regulatory frameworks, compliance requirements, and market-specific insights to guide strategic planning and operational setup.
      • Government & Trade Organizations : South Korean government agencies and trade bodies need market intelligence to support biotech industry development initiatives, policy formulation, and international competitiveness strategies.

      Reasons to Buy this Report

      • Market Size & Growth Trajectory : Gain precise valuation data for South Korea's market (USD 317.6M in 2025) with detailed CAGR projections through 2030, enabling accurate investment planning and competitive positioning in this high-growth region.
      • Competitive Landscape Intelligence : Understand South Korea-specific manufacturing capabilities, key players, and market dynamics to identify partnership opportunities, benchmark against local competitors, and optimize supply chain strategies.
      • Regulatory & Compliance Insights : Access detailed information on South Korea's MFDS regulatory requirements, GMP standards, and compliance frameworks essential for successful market entry and operational planning in this jurisdiction.
      • Strategic Investment Decisions : Leverage country-specific market data to evaluate expansion opportunities, facility investments, and partnership strategies tailored to South Korea's unique biotechnology ecosystem and growth drivers.
      • Demand & Capacity Analysis : Identify emerging demand segments, manufacturing capacity gaps, and service opportunities specific to South Korea's biopharmaceutical sector to guide product development and market entry strategies.

      Frequently asked questions

      What is the current market size of biopharmaceutical contract manufacturing in South Korea?

      South Korea's biopharmaceutical contract manufacturing market is valued at USD 317.6 million in 2025.

      What is the projected market size for South Korea by 2030?

      South Korea's market is projected to reach USD 481.5 million by 2030, representing 51.7% growth over the forecast period.

      What is the CAGR for South Korea's biopharmaceutical contract manufacturing market?

      South Korea's market is growing at a compound annual growth rate (CAGR) of 8.7% from 2025 to 2030.

      Why is South Korea an attractive location for biopharmaceutical contract manufacturing?

      South Korea offers advanced biotechnology infrastructure, a skilled workforce, strong regulatory expertise, government support for life sciences, and cost-effective high-quality manufacturing solutions.

      What factors are driving growth in South Korea's contract manufacturing sector?

      Key drivers include rising biologics investments, increasing pharmaceutical outsourcing trends, South Korea's strategic Asia Pacific position, and growing demand from multinational pharmaceutical companies.

      RESEARCH METHODOLOGY

      This research study extensively utilized secondary sources, directories, and databases to gather valuable information for analyzing the global biopharmaceutical contract manufacturing market. In-depth interviews were conducted with a variety of primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives from major market players, and industry consultants. These interviews were essential for obtaining and verifying critical qualitative and quantitative information, as well as assessing the growth prospects of the market. The global market size estimated through secondary research was then validated and refined using inputs from primary research to determine the final market size.

      Secondary Research

      Secondary research was primarily utilized to gather information for a comprehensive study focused on the biopharmaceutical contract manufacturing market, emphasizing technical and commercial aspects. The sources consulted for this research included Pharmaceutical Research and Manufacturers of America (PhRMA), European Federation of Pharmaceutical Industries and Associations (EFPIA), Bioprocess and Biosystems Engineering, Bioprocess International, PLOS Biology, European Medicines Agency (EMA), Pharma & Biopharma Outsourcing Association (PBOA), Generics and Biosimilars Initiative (GaBI), Parenteral Drug Association (PDA), American Association of Pharmaceutical Scientists (AAPS), Global Cancer Observatory, American Chemical Society, National Center for Biotechnology Information (NCBI), Food and Drug Administration (FDA), Biotechnology and Biological Sciences Research Council (BBSRC), and World Journal of Pharmaceutical Sciences.

      In addition to these sources, the study also included corporate and regulatory filings such as annual reports, SEC filings, investor presentations, and financial statements. Other resources included business magazines, research journals, press releases, and information from trade, business, and professional associations, along with analyses from MarketsandMarkets. These sources were instrumental in acquiring essential information about key market players, classifications, and segmentation based on industry trends, regional and country-level markets, market developments, and technological perspectives.

      Primary Research

      After conducting an initial assessment of the global biopharmaceutical contract manufacturing market through secondary research, we carried out comprehensive primary research. This involved conducting in-depth interviews with experts from the demand side, including stakeholders from pharmaceutical and biotechnology companies, contract research organizations (CROs), contract manufacturing organizations (CMOs), and academic and research institutions.

      Additionally, we interviewed key supply-side participants, such as C-suite executives, senior executives, product managers, and marketing and sales leaders from leading manufacturers, distributors, and channel partners. Our research focused on six major geographical regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while 30% involved demand-side experts.

      Data collection methods included structured questionnaires, email correspondence, online surveys, personal interviews, and telephone discussions to gain a comprehensive understanding of the market dynamics.

      The following is a breakdown of the primary respondents:

      Biopharmaceutical Contract Manufacturing Market

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both bottom-up and top-down approaches were used to estimate and validate the total size of the biopharmaceutical contract manufacturing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      • A list of the major global players operating in the biopharmaceutical contract manufacturing market was generated.
      • The revenues generated from their services have been determined through annual reports and secondary sources (including paid databases).
      • The services were mapped according to market segments. Percentage shares and splits were determined based on the revenue contributed to each segment. This was verified using secondary sources and industry experts.
      • All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.

      Global Biopharmaceutical Contract Manufacturing Market Size: Bottom-up and Top-down Approach

      Biopharmaceutical Contract Manufacturing Market

      Data Triangulation

      After estimating the total market size, it was divided into several segments and subsegments. To refine the overall market analysis and obtain accurate statistics for each segment and subsegment, we employed data triangulation and market breakdown procedures wherever applicable. This involved studying various factors and trends from both the demand and supply sides to validate the findings.

      Market Definition

      Biopharmaceutical contract manufacturing involves outsourcing biological manufacturing services to specialized organizations known as contract manufacturing organizations (CMOs). Biologics are intricate pharmaceutical products derived from living organisms, including proteins, peptides, nucleic acids, cells or tissues, and other molecules produced through biotechnology. The market study encompasses an assessment of various services, sources, types, scales of operation, molecules, and therapeutic areas within the field of biopharmaceutical contract manufacturing.

      Stakeholders

      • Pharmaceutical and Biotechnology Companies
      • Research and Consulting Firms
      • Academic Medical Centers
      • Government Research Organizations
      • Clinical Research Institutes
      • Contract Research Organizations
      • Pharmaceutical Distributors and Suppliers
      • Corporate Entities
      • Contract Development and Manufacturing Organizations

      Report Objectives

      • To define, describe, and forecast the biopharmaceutical contract manufacturing market based on service, type, source, scale of operation, molecule type, therapeutic area, and region
      • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the biopharmaceutical contract manufacturing market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions—North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To profile the key players in the global biopharmaceutical contract manufacturing market and comprehensively analyze their service portfolios, market positions, and core competencies
      • To track and analyze competitive developments such as service launches, expansions, agreements, and collaborations in the biopharmaceutical contract manufacturing market
      • To benchmark players within the biopharmaceutical contract manufacturing market using the company evaluation matrix framework, which analyzes market players based on various parameters within the broad categories of business and service strategy

       

      Get the Full Biopharmaceutical Contract Manufacturing Market Report

      Full forecast, segment splits, and company analysis for all Biopharmaceutical Contract Manufacturing Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status